Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ph.1, Open-Label, Dose Escalation & Expansion for Safety, Tolerability, PK, & Anti-Tumor Activity of STP707 Administered IV in Subjects With Advanced/Metastatic or Surgically Unresectable Solid Tumors Who Are Refractory to Standard Therapy.

Next Previous
Trial Profile

Ph.1, Open-Label, Dose Escalation & Expansion for Safety, Tolerability, PK, & Anti-Tumor Activity of STP707 Administered IV in Subjects With Advanced/Metastatic or Surgically Unresectable Solid Tumors Who Are Refractory to Standard Therapy.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 13 Jan 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs STP 707 (Primary)
  • Indications Colon cancer; Colorectal cancer; Liver cancer; Malignant melanoma; Ovarian cancer; Pancreatic cancer; Solid tumours; Uveal melanoma
  • Focus Adverse reactions
  • Sponsors Sirnaomics

Most Recent Events

  • 22 Dec 2025 According to a Sirnaomics media release, this trial, whic was conducted across 8 sites, has been completed and the Clinical Study Report (CSR) is formally submitted to the USFDA. With this submission the company is positioned to initiate discussions with the FDA to define the Phase 2 development strategy
  • 22 Dec 2025 According to a Sirnaomics media release, status changed from active, no longer recruiting to completed.
  • 28 Jun 2024 According to a Sirnaomics media release, the Group has completed a dose escalation study in 11 pancreatic cancer patients, conducted in 11 oncology clinics in the U.S. As per the preliminary results, strong safety profile and stable disease activity has been shown by STP707 for treatment of pancreatic cancer patients.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top